Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 6Phase 1/2 5Phase 2/3 3Phase 4 2Phase NA 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Multiple Myeloma 8Leukemia 6Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma 2Leukemia, T-Cell 2Waldenstrom Macroglobulinemia 1Vomiting 1Uterine Cervical Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Fatigue 1Congenital Abnormalities 1Breast Neoplasms 1Breast Carcinoma In Situ 1Brain Neoplasms 1

Interventions

Pemetrexed 13Carboplatin 13Docetaxel 11Cisplatin 11pembrolizumab 9Paclitaxel 8Gemcitabine 7Erlotinib Hydrochloride 4Bevacizumab 4anlotinib 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Gefitinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2cemiplimab 2auricularum 2atezolizumab 2apatinib 2Vemurafenib 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Ramucirumab 2Calcium Dobesilate 2trametinib 1toripalimab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Non-Small-Cell Lung × Dexamethasone × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07213375 2026-01-07

DEXTER

Rigshospitalet, Denmark

Phase 2/3 Recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡